Engineered immune cells injected directly into prostate tumors: a new hope?
NCT ID NCT07240857
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new treatment for castration-resistant prostate cancer (CRPC), a type that no longer responds to standard hormone therapy. Researchers are injecting specially engineered immune cells (CAR-T cells) directly into the prostate or tumor site, after a short course of chemotherapy. The study will enroll 18 people to check if the treatment is safe and whether it can lower PSA levels, a marker of prostate cancer activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ACT#001-PSMA CAR-T cells
- What this could lead to
- If successful, this could point toward a new treatment option for advanced prostate cancer that has stopped responding to hormone therapy.
- What could go wrong
- This is a very early, small trial (18 people) focused mainly on safety. The treatment may not shrink tumors or improve survival, and there are risks from chemotherapy and CAR-T cell side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo tame resistant prostate cancer?
- Can a radioactive 'Smart Bomb' shrink resistant prostate tumors?
- Old drug, new hope: niclosamide combo targets resistant prostate cancer
- AI could predict which prostate cancers turn aggressive
- New hope for hard-to-treat prostate cancer: drug combo trial launches
- New combo therapy aims to delay prostate cancer progression